Pesg releases market update: nuvectis pharma shows promising synergy for nxp900 in recent presentations; growing anticipation for upcoming nxp800 data update

London--(business wire)---- $drug #nasdaq--nuvectis pharma (nasdaq: nvct) is gaining momentum following recent presentations at the aacr-nci-eortc symposium, where its src/yes1 inhibitor nxp900 demonstrated strong synergy with alk inhibitors in nsclc cells that despite being driven by alk fusions, are resistant to treatment with the market leading alk inhibitors, alectinib (marketed by roche) and lorlatinib (marketed by pfizer). meanwhile, nxp800, the company's gcn2 activator, is progressing in a phase 1b trial.
DRUG Ratings Summary
DRUG Quant Ranking